It’s no surprise that many pharmaceutical companies are developing treatments for a disease affecting millions with no current therapy. That disease is Non-alcoholic fatty liver disease (NAFLD). NASH is a lifestyle disease (obesity and lack of exercise) and is distinct from other fatty liver diseases caused by alcohol abuse or medication side effects. The symptoms of NASH are often invisible until the liver is damaged beyond repair.
In Kalorama’s most recent report, published in January 2020, we looked at the drugs in development and potential markets for NASH drugs.
More Information can be found in Kalorama Information’s NASH Drugs Pipeline and Market Overview.
There are numerous products in development for the treatment of NASH. No medications have been approved specifically for NASH but some products such as pioglitazone and insulin sensitizers, Vitamin E and statins have been used to mitigate symptoms by controlling blood sugar and lowing lipid levels.
There are almost 80 products in development for the treatment of NASH. The bulk of products in development (41) are in Phase 2 clinical trials. Six products have moved on to Phase 3 and several of those have received Breakthrough Therapy Status or Fast Track Status.
The market for NASH treatments is difficult to predict due to a wide variety of variables and outcomes that could change as the industry progresses. Kalorama Information has determined the market size could reach $19.2 billion by 2025 using a variety of market indicators discussed throughout the report.
A number of trends will likely influence growth of the market including
- NASH disease incidence and prevalence
- NAFLD incidence and prevalence
- Risk factors
- Pricing trends
- Liver transplant statistics and trends
- Expected market penetration
- Global treatment options and emerging therapies
Companies that will likely have a competitive advantage in the NASH market include: